GLP2R/CRE-Luc/HEK293
CBP71432
詢 價(jià)
索取protocol
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| I. Background | |
|
G 蛋白偶聯(lián)受體(GPCR) 是跨膜蛋白受體，其特征是配體數(shù)量可變，包括內(nèi)源性神經(jīng)遞質(zhì)和激素，也包括外源性天然和人工化合物。激動(dòng)劑與受體結(jié)合后會(huì)觸發(fā)信號(hào)通路的激活；而拮抗劑則會(huì)阻礙激動(dòng)劑介導(dǎo)的受體激活。反向激動(dòng)劑除像拮抗劑一樣干擾激動(dòng)劑外，還會(huì)抑制受體的組成活性。
GLP2 受體 (GLP2R) 是 G 蛋白偶聯(lián)受體超家族成員，與胰高血糖素受體 ( GLP1 受體)密切相關(guān)。胰高血糖素樣肽-2 (GLP2) 是由腸道腸內(nèi)分泌細(xì)胞產(chǎn)生的 33 個(gè)氨基酸的胰高血糖素原衍生肽。GLP-2 通過特定的 G s 蛋白偶聯(lián)受體（GLP-2R）發(fā)揮作用，維持腸道穩(wěn)態(tài)和屏障功能，減緩胃排空和腸道蠕動(dòng)，改善粘膜血流和營養(yǎng)吸收，增強(qiáng)免疫防御能力。
|
|
| II. Description | |
|
GLP2R CRE-Luc HEK293 報(bào)告基因藥靶模型很好的模擬了體內(nèi) GLP2R 的信號(hào)轉(zhuǎn)導(dǎo)過程，原理見下圖所示。
 Figure 1. GLP2R CRE-Luc HEK293 細(xì)胞模型原理圖 |
|
| III. Introduction | |
| Host Cell: |
HEK293 |
| Stability: | 20 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | DMEM+10%FBS+2ug/ml puromycin+200ug/ml hygromycin |
| Mycoplasma Status: | Negative |
| Storage: | Liquid nitrogen immediately upon delivery |
| Application(s): |
Functional assay for GLP2R |
| Assay Format: | Gs |
| IV. Description of Host Cell Line | |
| Organism: | Homo sapiens, Human |
| Tissue: | Embryonic kidney |
| Morphology: | Epithelial |
| Growth Properties: | Adherent |
| V. Representative Data | |
|
Figure 2. Recombinant GLP2R/CRE-Luc/HEK293 stably expressing GLP2R. |
|
|
Figure 3. Dose response of GLP-2(1-33) (Human) in GLP2R CRE-Luc HEK293 Cells (C7). |
|
